Oncology Xagena
The first-in-human results from a dose escalation study of Avitinib, a third generation irreversible epidermal growth factor receptor ( EGFR ) inhibitor that has been shown to overcome T790M-induced r ...
Sedation is used to an increasing extent in end-of-life care. Definitions and indications in this field are based on expert opinions and case series. Little is known about this practice at palliativ ...
The idea that a non-Platinum therapy might artificially extend the Platinum-free interval, thereby improving outcomes in ovarian cancer patients who experience recurrence between 6 and 12 months after ...
Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...
Immune checkpoint inhibitors rely on the presence of ongoing immune response to exert their antitumor effect. Little is known whether an age-related decline in immune function negatively influences ...
With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...
New patient-reported quality-of-life data from an exploratory endpoint in the pivotal phase 3 CheckMate -141 trial evaluating Nivolumab ( Opdivo ) in patients with recurrent or metastatic squamous cel ...
A treatment harnesses the immune system to shrink tumors in bladder cancer patients that cannot take the most effective chemotherapy. These are the findings of a clinical trial led by researchers at ...
Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...
Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...
Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening or death ( progression free survival, PFS ) by 66% compared to Crizotinib ( Xalk ...
A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with Panitumumab plus Vemurafenib. Pre-existing cells with increased MET gene copy ...
The results for Nivolumab ( Opdivo ) in the cohort of patients with metastatic urothelial cancer ( n=78 ), the most common type of bladder cancer, after Platinum-based therapy from CheckMate -032, a p ...
Interim data from the phase 2 CheckMate -142 trial evaluating Nivolumab ( Opdivo ) alone or in combination with Ipilimumab ( Yervoy ) in patients with previously treated metastatic colorectal cancer, ...
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer and have been treated with combination Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX)-base ...
